Cost-Effectiveness Analysis of Pembrolizumab for BCG-Unresponsive Carcinoma in Situ of the Bladder.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Urology"
DOI: 10.1097/ju.0000000000001515
Abstract: PURPOSE Patients with BCG-unresponsive carcinoma in situ (CIS) are treated with radical cystectomy (RCx) or salvage intravesical chemotherapy (SIC). Recently, pembrolizumab was approved for BCG-unresponsive CIS. MATERIALS AND METHODS We used a decision-analytic Markov model… read more here.
Keywords: bcg unresponsive; pembrolizumab; cost effective; rcx ... See more keywords